Wendy Verret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wendy Verret has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Brian Stwalley
Gilead Sciences, Inc. 6 Department of US Medical Affairs Foster City, California
7 shared publications - Elizabeth C. Dabrowski
Aetion, Inc. 3 Scientific Engagement New York, New York
7 shared publications - Gregory A. Vidal
Clinical Research and Breast Oncology Program, Lee S Schwartzberg Research Center, West Cancer Center and Research Institute, Memphis, Tennessee
7 shared publications - Julie Katz
Gilead Sciences, Inc. 2 Real World Evidence Oncology Foster City, California
7 shared publications - Kevin Kalinsky
Winship Cancer Institute at Emory University, Atlanta, USA
7 shared publications - Natalia Sadetsky
Gilead Sciences, Inc. 2 Real World Evidence Oncology Foster City, California
7 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing the definitions used for each US geographic region
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A schematic diagram of patient disposition and exclusion criteria
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background:Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors.Methods:A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods.Results:The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed.Conclusions:We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings.Impact:These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
A table showing baseline demographics and disease characteristics divided by SES index
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Additional detail on the methodology for subgroup analyses and statistical analyses
- Open Access
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.
- 29 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 35 (4) , 588-596
Open AccessSociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer
Background: Various factors such as race/ethnicity, practice settings, socioeconomic status (SES), and geographic region influence cancer outcomes. We describe treatment patterns and outcomes among women with hormone receptor–positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer treated in the United States based on these factors. Methods: A retrospective, observational cohort study was conducted using the Flatiron Health Research Database of deidentified electronic health records in women ≥18 years in the United States who received first-line treatment for HR+/HER2− metastatic breast cancer from January 1, 2015, to February 28, 2023. Real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) were assessed using Kaplan–Meier methods. Results: The analysis included 6,974 women, who were most commonly non-Hispanic White (64%), lived in the South (37%), and received treatment in community settings (83%). From 2015 to 2019, the early uptake period of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), non-Hispanic White women were more likely to receive endocrine therapy (ET) + CDK4/6i compared with non-Hispanic Black and Hispanic/Latino women; ET + CDK4/6i was less common in lower (Q1–Q3) versus higher (Q4–Q5) SES quintiles and in community versus academic settings. These differences were less pronounced from 2020 to 2023. Non-Hispanic White women had significantly longer rwOS compared with non-Hispanic Black women but shorter rwOS compared with Hispanic/Latino women. rwOS was longer in academic versus community settings. No substantial differences in rwTTNTD were observed. Conclusions: We observed disparities in first-line treatment and outcomes among women with HR+/HER2− metastatic breast cancer during a time of changes to the standard of care across racial/ethnic groups and practice settings. Impact: These findings emphasize the need for improved access to evidence-based therapies, particularly in underrepresented populations.